Aerosol medication inhalation system

Information

  • Patent Grant
  • 8973571
  • Patent Number
    8,973,571
  • Date Filed
    Thursday, May 23, 2013
    11 years ago
  • Date Issued
    Tuesday, March 10, 2015
    9 years ago
Abstract
An apparatus for use in conjunction with a metered dose inhaler which includes a novel valve system to aid in the delivery of aerosolized medicament to a subject. The apparatus also includes a novel rotational flow generator to aid in the useable delivery of said medication and avoid its loss either in the apparatus or by non-useful delivery to said subject.
Description
BACKGROUND

The present invention is directed to apparatus for delivering aerosol medicament to a subject in need of the medicament. Delivery systems start with an aerosol-generating device. One common example of such devices is a pressurized metered dose inhaler (MDI). MDIs use pressurized gases to disperse medicament as tiny particles or droplets for delivery to the subject. By depressing the MDI, a known quantity of gas, and thereby of medicament, is ejected from the MDI. MDIs have been used with various types of diverse apparatus, in attempts to improve the delivery of this known quantity of medicament to the subject. Some problems associated with the delivery of medicament in an aerosol form include, but are not limited to, wastage of medicament in the delivery apparatus, delivery at too high speeds so that medicament sticks to the back of the subject's throat or is inhaled into the subject's sinuses rather than being received into the lungs, ejection of medicament out of the apparatus towards a subject without inhalation thereby, and ejection of medicament from the MDI upon exhalation by the subject into the apparatus prior to inhalation.


SUMMARY OF THE INVENTION

In one aspect, the present invention provides a mouthpiece with a valve for controlling the delivery of aerosolized medicament to a subject. The mouthpiece includes a housing that defines a passage through which the medicament flows to the subject. The housing has a one-piece valve system that permits passage of medicament aerosol to the subject during inhalation, but does not permit the passage of the subject's breath in the upstream direction during exhalation, with the exhaled breath being expelled through an opening in the sidewall of the housing.


Another aspect of the present invention combines this mouthpiece and valve system with a holding chamber, which is disposed between the mouthpiece and the source of aerosol. In a further feature of this aspect of the invention, the interior of the holding chamber has anti-electrostatic properties to reduce the amount of medicament adhering to the walls of the holding chamber and thereby increase the delivery efficiency of the system.


In a further aspect of the present invention, a holding chamber is provided with a receptacle member adapted to accept a source of aerosol medicament. The receptacle member may aid in the efficient delivery of medicament to the subject, for example by being vented to allow outside air to be mixed with the medicament aerosol in the holding chamber. In addition, if a rotation is imparted to the outside air brought into the holding chamber, the adhesion of medicament to the walls of the holding chamber can be reduced and the effort necessary to inhale through an apparatus of this type may be reduced.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an assembled view of an example of the aerosol medicament delivery apparatus of the present invention.



FIG. 2 is a perspective exploded view of the apparatus.



FIG. 3 is a side view of the delivery member used in the apparatus.



FIG. 4 is a bottom perspective view of the delivery member.



FIGS. 5
a and 5b are top and bottom views of the valve element used in the apparatus.



FIG. 6 is a top perspective view of the delivery member.



FIG. 7 is a sectional side view of the adaptor member used in the apparatus.



FIG. 8 is a top perspective view of the adaptor member.



FIGS. 9
a and 9b are top and bottom views of the receptacle member used in the apparatus.





DETAILED DESCRIPTION

Referring to FIGS. 1 and 2, the aerosol medicament delivery apparatus 10 of the present invention is composed of a holding chamber 200 with first and second ends. At the first end of the holding chamber is a receptacle 300 for connection to a source of aerosol medication. For the purposes of the present invention, aerosol medicament or aerosol medication is intended to include finely divided solid or liquid materials that are carried by a gas for delivery to a subject's respiratory tract, especially to the lungs. This includes nebulized materials. The medicament and carrier gas aerosol composition can be prepared prior to use if it exhibits sufficient physical and chemical stability, or it can be prepared in situ from sources of solid or liquid medicament materials (either in pure form or combined with a suitable solid or liquid solvent, excipient or diluent) and pressurized gas.


At the second end is a mouthpiece member 100 for delivering aerosol medicament to a subject through a valve 150. The mouthpiece member includes a housing 101 that defines a passage 102 through which aerosol medicament can be supplied to a subject and has an opening 103 that opens to the outside of the housing. The valve, discussed below, is of one-piece construction. During inhalation the valve permits the flow of aerosol medicament from the holding chamber to the subject, while blocking the inflow of outside air to the passage 102 through the sidewall of the housing of the mouthpiece member. During exhalation, the valve blocks the flow of exhaled air upstream in the direction of the holding chamber, and permits the exhaled air to be exhausted through the sidewall of the housing.


In an exemplary embodiment, the housing 101 is composed of a delivery member 110 and an adaptor member 170. The opening 103 may be defined, as it is in part in the exemplary embodiment, by a notch 186 in the adaptor member. The delivery member and adaptor member may be releasably connected by a quick release mechanism 182. In the exemplary embodiment, the quick release mechanism is a flexible wall, upon which a positioning element 175 may be located. Also, in the exemplary embodiment, the housing is transparent. This has the advantage that it allows for the subject to visually verify the operation of the valve, to ensure opening and closing during treatment.


Referring to FIG. 3, the delivery member 110 may include a subject side section 120, a connecting ring 130, and an adaptor side section 140. In the exemplary embodiment, the subject side section of the delivery member of the mouthpiece is sized and shaped to fit a human mouth, e.g. having an oval shape. The subject end section is defined by a housing composed of a sidewall having a height 124, and upon which may be provided at least one ridge 125. Positioning pins 141 may be provided on the adaptor side section of the delivery member.


Referring to FIG. 4, the adaptor side section 140 of the delivery member 110 in this exemplary embodiment has walls 142 arranged around an opening 145. One or more openings, for example the illustrated notches 147, is formed in the wall 142 and can define an exhaust opening from the delivery member for exhaled air. This opening is closed by the valve during inhalation, and the opening may be provided with an element to assist in seating a valve member, for example protrusion 146. The end face 144 of the wall can be used as a surface for holding the valve in place when the apparatus is assembled, in cooperation with an opposed surface on the adaptor member. Also, in this embodiment, the four positioning pins 141 extend from the end face of the wall 142.


Referring to FIGS. 5a and 5b, the one-piece two-way valve system 150 allows for inhalation and exhalation with a single valve. The valve has a base 151, a first valve element 152, which has a duck-bill shape in this embodiment, and a second valve element 153, which is shaped like a hinged flap 153 in this embodiment. In the exemplary embodiment, the valve is composed of a flexible material and there are two hinged flaps 153. The two valve elements may be joined at or carried on a common base 151. The base has a thickness 154 that is less than the height of the positioning pins of the mouthpiece, so that the pins may pass therethrough. There is an opening 155 in the base, which may be defined as the perimeter of contact between the duck-bill and the base. The exemplary embodiment has four positioning holes 156 placed near the perimeter of the base, each being sized to admit the matching positioning pins. Thus, when the apparatus is assembled, the positioning pins of the mouthpiece penetrate the positioning holes of the valve base and the valve base forms a substantially airtight seal between the delivery member and the adaptor member.


The duck-bill is a shape predominantly that of a wedge with a very narrow split across the apex of the wedge. The split is narrow enough that the two edges forming the ends of the duck-bill are substantially in contact when there is no external pressure on the duck-bill. The duck-bill has a span, a height, and a thickness. The height of the duck-bill is the vertical distance between the apex of the wedge where the split is located and the base. The span is the distance of the split across the thin edge of the wedge and the height. The span is sufficiently narrow that the apex of the duck bill will fit within the delivery member without contacting it. Thus, the dead zone within the delivery member is minimized by the valve extending therein. The valve may be as wide as possible to provide for easier inhalation, but just narrower than the passage so that the duck-bill sides do not receive pressure and the lips of the duck-bill are not parted except by inhalation.


Dead space refers to the volume of the apparatus containing air which is rebreathed. Dead space is inherent in any valve-based system enclosed within a mouthpiece or mask; it is the space between the mouth of a subject and the valve. Any subject has a limited volume of air that may be inhaled, and which then is exhaled. This is the subject's tidal volume. The inhalation air will contain both oxygen and medicament. The exhalation air will contain carbon dioxide. In a sealed system, all inhalation air will come through the valve and will contain a preferable mixture of medicament laden air. However, this inhalation air will be combined with whatever gases remain sealed within the dead space on their way to being actually inhaled into the subject's respiratory tract. Similarly, when the subject exhales, all air must pass through this dead zone on the way out the exhaust portion of the valve system.


Because the subject will be incapable of forcing a complete vacuum within this sealed system, the dead space will contain gases that then will be re-inhaled during the next breathing cycle. Given that the volume of the subject's lungs is fixed, the larger the volume of the system's dead space, the smaller the volume of medicament laden air the subject will receive with each breathing cycle. Thus, the larger the volume of dead space, the less efficient the system because increasing dead space causes a buildup of carbon dioxide and rebreathing. Rebreathing carbon dioxide can have an adverse effect on breathing rates and patterns, especially for small children who have very small tidal volumes. Duck-bill valves are more efficient than diaphragm valves because the volume encompassed by the duck-bill is subtracted from space that otherwise would be dead space in a diaphragm-based system.


The duck-bill is thin enough that the sides of the wedge will flex when the atmospheric pressure on the opposite side of the base from the duck-bill is greater than that above the duck-bill. This causes the edges of the duck-bill to part, letting air flow through the duck-bill in the direction from the base to mouthpiece. Thus, in the present embodiment, air is permitted to flow through the mouthpiece to a subject during inhalation. The duck-bill closes automatically at the end of inhalation when the atmospheric pressure differential is removed. Thus, the flow of exhaled air upstream of the valve to the holding chamber is prevented during exhalation.


The exemplary embodiment of the present invention provides two hinged flaps 153 extending from on or near the perimeter of the base. Each hinged flap 153 is sized so as to be able to cover a corresponding notch 147 when assembled. Each flap is placed on the base at such a position and at such an angle that when the base is placed onto the positioning pins of the mouthpiece, the flap covers one of the notches 147. The flap is hinged onto the base so that it may cover the notch 147 during inhalation, thereby preventing the flow of outside air into the interior of the housing through the opening in the sidewall of the housing. When the mouthpiece of the apparatus of the exemplary embodiment is assembled, the notch of the delivery member 147 and the aforementioned notch of the adaptor member 186 may be aligned radially, and the hinged outgas flap 153 is disposed between these notches. The flexible material forming each of the outgas flaps is sufficiently thin to allow an outgas flap to flex through at least a few degrees of flexibility when differences in relative atmospheric pressure caused by human breathing exert flexing pressure on said flap, thereby moving the flap away from the notch 147 during exhalation and allowing exhaled air to pass out of the mouthpiece through the notch 186.


Referring to FIG. 6, the subject side section 120 of the delivery member may be formed by a sidewall 128 that is generally cylindrical in shape with an oval cross section. The exemplary embodiment has two side points 122, opposite each other on the sidewall, and two lip points 123, opposite each other on the sidewall. Each lip point is equidistant between the two side points. There is a contact end 126 where the sidewall is joined to the connecting ring and a lip end 127 opposite the contact end. The upper opening of the sidewall 121 at the lip end is oval. There is a lower opening of the sidewall at the contact end, through which the tip of the duck-bill valve passes.


Ridges 125 may be provided for placement of the subject's lips, or to aid in the placement of an adaptor mask on the outside of the delivery member. Shaped correctly, a ridge 125 may be used to seal and mount such a mask with a tight pressure fit. These ridges are placed approximately halfway down the upper section, and are wedge shaped in the exemplary embodiment. Specifically, they are formed by the upper and lower thickness measurements being equal at the side points and the lower thickness being greater than the upper thickness at the lip points.


Referring to FIGS. 4 and 6, the connecting ring 130 between the adaptor side and subject side sections of the delivery member has an interior opening 135, which may be equal in size to and substantially continuous with the opening of the sidewall of the subject side section. It has an exterior limit 131 that is greater than the interior opening, and a surface 132 where the connecting ring is joined to the subject side section. The surface 132 extends from the sidewall 128 outwards toward the exterior limit 131 where it joins with an exterior wall 133.


The exterior wall 133 may be substantially parallel to the sidewall 128 and extends from the top surface in a direction away from the lip end of the subject side section. The exterior wall has an interior surface and an exterior surface, the interior surface being closer to the interior opening of the connecting ring. In the exemplary embodiment, there are two contact openings 134 in the top surface, which are disposed approximately equidistantly around the circumference of the top surface. Each contact hole is adapted to accept a portion of the adaptor member, to help hold the two members of the mouthpiece securely together. On the interior surface of the exterior wall, there may be provided two engaging members 136, or catches, each being below a contact hole. They are wedge shaped and oriented with the thin end of the wedge towards the adaptor side for ease in connecting and resistance to disconnecting. In the exemplary embodiment, each has a width less than that of the corresponding contact opening above the catch, a length less than that of the distance between the top and bottom of the exterior wall of the connecting ring, and a height less than the length.


Referring back to FIGS. 3 and 4, the width 143 of each section that makes up the wall 142 is approximately as wide as a contact opening in the top surface of the connecting ring. Each wall section is disposed along the interior opening substantially adjacent to a contact opening, thus providing a limit to the flexing of the walls of the adaptor member, which is discussed below. In the exemplary embodiment, each wall section has two positioning pins 141 placed along the end face of the wall, extending in the same direction. They are placed near the edge of the wall sections, and can be placed as far apart from each other as the width of a contact opening in the surface of the connecting ring. Due to their height, the sections of the wall 142 extend into the space of the adaptor member when the apparatus is assembled. Protrusions 146 may be disposed on the perimeter of the opening forming the passage for exhalation air flow (notches 147). These protrusions act as stop elements for the exhaust flap portions of the one-piece valve, limiting their travel in an inward direction. As will be seen in more detail below, when the subject inhales, these exhaust flaps are pressed by suction against the stop elements and form a seal so that the pressure of inhalation is fully directed towards drawing the medicament laden air from the holding chamber.


Referring to FIG. 7, the adaptor member 170 may be generally frustoconical in shape, thereby providing for the smooth change in diameter from the holding chamber to the delivery member. In the exemplary embodiment, it is both frustoconical and transparent. A transparent embodiment of the present invention has the additional advantage of allowing the subject to visually verify the presence of the medicament during delivery to the patient. The adaptor member may have a base end 171, a conical midsection 172, four wall sections, and a delivery side end 173. The base end is adapted to cooperate with the edge of the holding chamber, for example forming an exterior wall extending from the end of the cone. The base end of the adaptor member also may have an inner wall 174 extending from the end of the cone. In the exemplary embodiment, each of these two walls having a height of at least 0.5 mm to define a groove for accepting the edge of the holding chamber. In this case, the walls are shaped and positioned such that, when the chamber is positioned between the inner and outer walls and a thin layer of adhesive is applied between the walls, a substantially airtight seal may be formed between the holder and the chamber. Other systems for joining the adaptor member and holding chamber may be used, including permanent bonding or releasable connections. The releasable connection may not be needed when the delivery member is made of two readily-separated components that allow for easy cleaning and for replacement of the valve when necessary, as in the illustrated embodiment.


Referring to FIGS. 7 and 8, the wall arising from the frustoconical midsection 172 of the adaptor member 170 may be divided into four sections, including two catch walls 176 and two vent walls 177 in the exemplary embodiment. These may be placed alternately around the delivery side end of the adaptor member. Each catch wall 176 may have a catch opening 178 sized to admit one of the catches 136 of the connecting ring 130 of the delivery member 110. A catch wall 176 is positioned on the adaptor member such that its opening 178 is adapted to fit a catch 136 when the two adaptor and delivery members are joined. The end 179 of the catch wall 176 may fit a contact opening 134 of the connecting ring 130 of the delivery member 110. The catch walls 176 may be flexible, so that they may be bent by the subject applying pressure at the positioning points 175 to release the catch 136 from the opening 178. This allows the two members of the exemplary housing 101 to be joined and separated in a quick-release fashion. Each valve wall 177 in the exemplary embodiment is U shaped. That is, it is a wall on the long side of the oval opening with a notch 186 in it. Other systems for connecting the adaptor member and delivery member can be used. In addition, the catch and opening could be reversed, i.e. the opening provided on the connecting ring and the catch provided on wall section of the adaptor member.


The delivery side end of the conical adaptor member may have an opening 185 of substantially the same size as the opening 155. An airtight seal may be formed between the opposing surfaces of the adaptor member and the delivery member by the valve. That is, the valve base 151 may have opposing surfaces arranged to meet those of the adaptor member and the delivery member and form an airtight seal when the apparatus is assembled. The exemplary embodiment's adaptor member 170 has a rim 180 around the opening 185 with four positioning openings 181 in the rim, one for each pin 141. Thus, when the two members are joined, the four pins of the delivery member drop into these openings in the exemplary embodiment.


Referring to back FIGS. 1, 2 and 7, the cylindrical holding chamber 200 may be defined by a length of cylindrical tube that extends between the mouthpiece 100 and a source of aerosol medicament and includes the receptacle 300 accepting an outlet from a source of aerosol medicament such as a metered dose inhaler or the like. The tube wall 201 may be sized to fit between the inner wall 174 and the outer wall 171 of the base of the mouthpiece. In the exemplary embodiment, the holding chamber is made of a lightweight metal or alloy, such as aluminum or an alloy thereof.


The use of such material reduces the risk of resistance to medicament flow by static attraction between the particles of medicament and the holding chamber wall. Alternatively, the surface of a holding chamber of any material may be treated with an anti-electrostatic coating or process to achieve this advantage. In the exemplary embodiment using a metal tube, the tube is anodized which provides the advantage of sealing the micro-porosity of such a tube's surface and stabilizing it against oxidation.


Referring to FIGS. 9a and 9b, the receptacle 300 may include a base with a lip 310, an opening 350 for accepting a source of aerosol medicament in the base with a collar 370 extending into the chamber 200, an air vent 320, and a supporting wall 340 that surrounds the opening arising from the base into the chamber. The exemplary embodiment has four vents. The receptacle base is sized to fit within the tube of the holding chamber. It may be formed of a resilient and flexible material such that it may be removed from the chamber tube (e.g., for cleaning) and replaced many times without loss of functionality, such as maintenance of structural integrity or the ability of the receptacle to form a substantially airtight seal with the tube, throughout the life of the apparatus. In the exemplary embodiment, the receptacle may be removed and replaced hundreds of times without ripping, tearing or otherwise harming the functionality of the apparatus. This removal resilience also applies to the removal and replacement of the source of aerosol medicament from the apparatus. The lip 310 of the receptacle fits around the perimeter of the base of the member so that the lip extends beyond the edge of the tube. The lip may be sized such that it forms a substantially airtight seal with the tube. Other systems can be used to join the receptacle to the tube if desired.


The opening 350 of the receptacle of the exemplary embodiment may be sized to accept several different types of aerosol medicament sources such as MDIs. The collar 370 is sufficiently long and flexible to form a seal with the aerosol medicament source when one is admitted into the receptacle. The supporting wall 340 of the exemplary embodiment is provided with cyclone baffles 330 placed upon the outside of the wall (relative to the opening) and support ribs 360 radially placed upon the inside of the wall. The support ribs 360 extend from the wall towards the collar 370. They are sized so that there is space for the collar to be pressed up against the ribs when a typical MDI is inserted into the opening. Thus, an airtight seal may be formed around the source of the aerosol medicament. The support ribs of the exemplary embodiment provide support to the source of aerosol medicament by holding that source against the structure of the collar.


The vents 320 allow outside air to be drawn into the holding chamber during inhalation. This helps to push the aerosol medicament to the subject during inhalation. Each cyclone baffle 330 extends towards the base and is aligned with a vent 320 so that the point where the baffle reaches the base is just beyond the vent. The baffle thus covers the vent. The baffle may have a width sufficient to form a seal between the supporting wall and the tube wall of the chamber. By using the baffle to direct airflow coming through the vents, a rotational flow is imparted to the air entering the chamber through the vents. In the exemplary embodiment, the placement of the cyclone baffles above the vents and next to the wall of the holding chamber wall directs outside air to and along the wall of the holding chamber. This reduces the tendency for medicament to adhere to the wall of the holding chamber. Although each of the four vents have been provided with a cyclone baffle in the present embodiment, this may not be necessary in all cases.


The exemplary embodiment of the present invention is steam autoclavable either assembled or disassembled. This advantage arises from both the choice of materials used, as herein discussed, and the materials and methods of assembling the components of the invention, such as the quick release mechanism 182 and the use of high-temperature adhesive at the junction of adaptor member 170 and holding chamber 200. Further, the present invention is easily disassembled for cleaning and parts replacement by a non-technical person.


While a detailed description of the present invention has been provided above, the invention is not limited thereto. Modifications that do not depart from the scope and spirit of the invention will be apparent to those skilled in the art. The invention is defined by the claims that follow.

Claims
  • 1. A medication delivery apparatus comprising: an antistatic holding chamber that has an input end and an output end spaced apart along a longitudinal axis;a patient interface component connected to said output end and comprising an interior surface defining a flow passage; anda duck-bill shaped valve disposed adjacent said output end, said duck-bill shaped valve comprising a flexible material and moveable between an open position and a closed position, wherein said duck-bill shaped valve has a central opening when in said open position, said central opening having a flow path along said longitudinal axis, so as to facilitate a flow from the antistatic holding chamber to a patient,wherein the duck-bill shaped valve is configured to block a flow of exhaled air upstream in the direction of the antistatic holding chamber, and the duck-bill shaped valve configured to permit the exhaled air to be exhausted through a sidewall of a housing.
  • 2. The apparatus of claim 1, further comprising a backpiece separate from said holding chamber and comprising an elastomeric material having a surface resistivity that reduces a risk of resistance to medicament flow, wherein said backpiece is connected to said input end of said holding chamber.
  • 3. The apparatus of claim 2, wherein said backpiece comprises an opening formed therethrough, said opening shaped and adapted to receive a portion of a pressurized metered dose inhaler.
  • 4. The apparatus of claim 1, further comprising a second antistatic component separate from said holding chamber and comprising a material having a surface resistivity that reduces a risk of resistance to medicament flow, and wherein said second antistatic component is connected to said holding chamber.
  • 5. The apparatus of claim 4, wherein said second antistatic component comprises said patient interface component connected to said output end of said holding chamber.
  • 6. The apparatus of claim 4, wherein said second antistatic component comprises a backpiece connected to said input end of said holding chamber.
  • 7. The apparatus of claim 6, wherein said backpiece comprises an elastomeric material.
  • 8. The apparatus of claim 6, wherein said backpiece comprises an opening formed therethrough, said opening shaped and adapted to receive a portion of a pressurized metered dose inhaler.
  • 9. The apparatus of claim 1, wherein said patient interface component comprises a mouthpiece.
  • 10. The apparatus of claim 9, wherein said interior surface of said mouthpiece is not antistatic.
  • 11. The apparatus of claim 1, wherein the duck-bill shaped valve is configured to form a wedge, the wedge having sides that are configured to flex when atmospheric pressure on one side of the duck-bill shaped valve is greater than atmospheric pressure on an opposite side of the duck-bill shaped valve.
  • 12. The apparatus of claim 1, further comprising a receptacle comprising a flexible material positioned at the input end of said antistatic chamber and configured to accept a source of medication.
  • 13. The apparatus of claim 12, wherein said receptacle is configured to be removed from said antistatic chamber for replacing the receptacle.
  • 14. A medication delivery apparatus comprising: an antistatic holding chamber that has an input end and an output end spaced apart along a longitudinal axis;a patient interface component connected to said output end and comprising an interior surface defining a flow passage;a duck-bill shaped valve disposed adjacent said output end, said duck-bill shaped valve comprising a flexible material and moveable between an open position and a closed position, wherein said duck-bill shaped valve has a central opening when in said open position, said central opening having a flow path along said longitudinal axis, so as to facilitate a flow from said antistatic holding chamber to a patient, wherein said duck-bill shaped valve is configured to block a flow of exhaled air upstream in the direction of said antistatic holding chamber; anda receptacle comprising a flexible material positioned at the input end of said antistatic holding chamber and configured to accept a source of medication.
  • 15. The apparatus of claim 14, further comprising an adaptor positioned between said patient interface and said antistatic holding chamber, said adaptor comprising a housing configured with a vent.
  • 16. The apparatus of claim 15, wherein said duck-bill shaped valve is configured to permit the exhaled air to be exhausted through said vent.
  • 17. The apparatus of claim 14, further comprising a backpiece separate from said holding chamber and comprising an elastomeric material having a surface resistivity that reduces a risk of resistance to medicament flow, wherein said backpiece is connected to said input end of said antistatic holding chamber, wherein said backpiece comprises an opening formed therethrough, said opening shaped and adapted to receive a portion of a pressurized metered dose inhaler.
  • 18. The apparatus of claim 14, further comprising a second antistatic component separate from said antistatic holding chamber and comprising a material having a surface resistivity that reduces a risk of resistance to medicament flow, and wherein said second antistatic component is connected to said antistatic holding chamber.
  • 19. The apparatus of claim 14, wherein said receptacle is configured to be removed from said antistatic holding chamber for replacing the receptacle.
  • 20. A medication delivery apparatus comprising: an antistatic holding chamber that has an input end and an output end spaced apart along a longitudinal axis;a patient interface component connected to said output end and comprising an interior surface defining a flow passage;a duck-bill shaped valve disposed adjacent said output end, said duck-bill shaped valve comprising a flexible material and moveable between an open position and a closed position, wherein said duck-bill shaped valve has a central opening when in said open position, said central opening having a flow path along said longitudinal axis, so as to facilitate a flow from said antistatic holding chamber to a patient, wherein said duck-bill shaped valve is configured to block a flow of exhaled air upstream in the direction of said antistatic holding chamber; andan adaptor positioned between said patient interface and said antistatic chamber, said adaptor comprising a housing configured with a vent.
  • 21. The apparatus of claim 20, wherein said duck-bill shaped valve is configured to permit the exhaled air to be exhausted through said vent.
  • 22. The apparatus of claim 20, further comprising a receptacle comprising a flexible material positioned at the input end of said antistatic holding chamber and configured to accept a source of medication.
  • 23. The apparatus of claim 22, wherein said receptacle is configured to be removed from said antistatic holding chamber for replacing the receptacle.
CROSS REFERENCE TO PRIOR APPLICATIONS

This application is a Continuation Application of U.S. patent application Ser. No. 13/288,479, filed Nov. 3, 2011, which is a Continuation Application of U.S. patent application Ser. No. 12/332,976, filed Dec. 11, 2008, now issued as U.S. Pat. No. 8,074,641, which is a Continuation Application of U.S. patent application Ser. No. 10/943,542, filed Sep. 17, 2004, now issued as U.S. Pat. No. 7,562,656, which is a Continuation Application U.S. patent application Ser. No. of 10/137,007, filed May 2, 2002, now abandoned, all of which are incorporated herein by reference. A claim of priority to all, to the extent appropriate is made.

US Referenced Citations (284)
Number Name Date Kind
393369 Hawkins Nov 1888 A
2535844 Emerson Dec 1950 A
2670739 McNeill Mar 1954 A
2882026 Eichelman Apr 1959 A
3236458 Ramis Feb 1966 A
3269665 Cheney Aug 1966 A
3363833 Laerdal Jan 1968 A
3556122 Laerdal Jan 1971 A
3580249 Takaoka May 1971 A
3584621 Bird Jun 1971 A
3630196 Bird Dec 1971 A
3643686 Koegel Feb 1972 A
3658059 Steil Apr 1972 A
3664337 Lindsey et al. May 1972 A
3809084 Hansen May 1974 A
3809294 Torgeson May 1974 A
3826255 Havstad et al. Jul 1974 A
3838686 Szekly Oct 1974 A
3874379 Enfield et al. Apr 1975 A
3896101 McIntosh et al. Jul 1975 A
3897779 Hansen Aug 1975 A
3903884 Huston et al. Sep 1975 A
3990442 Patneau Nov 1976 A
3994421 Hansen Nov 1976 A
4081233 Kitajima et al. Mar 1978 A
4093124 Morane et al. Jun 1978 A
4094317 Wasnich Jun 1978 A
4106503 Rosenthal et al. Aug 1978 A
4116387 Kremer, Jr. et al. Sep 1978 A
4150071 Pecina Apr 1979 A
4165961 Yamamoto et al. Aug 1979 A
4174712 Moren et al. Nov 1979 A
4182366 Boehringer Jan 1980 A
4198969 Virag Apr 1980 A
4231375 Boehringer et al. Nov 1980 A
4251033 Rich et al. Feb 1981 A
4267832 Hakkinen May 1981 A
4268460 Boiarski et al. May 1981 A
4275722 Sorensen Jun 1981 A
4292966 Mono et al. Oct 1981 A
4298023 McGinnis Nov 1981 A
4333450 Lester Jun 1982 A
4344573 De Felice Aug 1982 A
4413784 Dea Nov 1983 A
4429835 Brugger et al. Feb 1984 A
4470412 Nowacki et al. Sep 1984 A
4496086 Duchadeau Jan 1985 A
4507118 Dent Mar 1985 A
4509515 Altounyan et al. Apr 1985 A
4509688 Gagne et al. Apr 1985 A
4533082 Maehara et al. Aug 1985 A
4588129 Shanks May 1986 A
4620670 Hughes Nov 1986 A
4635631 Izumi Jan 1987 A
4637528 Wachinski et al. Jan 1987 A
4641644 Andersson et al. Feb 1987 A
4646644 Richmond et al. Mar 1987 A
4657007 Carlin et al. Apr 1987 A
4674491 Brugger et al. Jun 1987 A
4677975 Edgar et al. Jul 1987 A
4746067 Svoboda May 1988 A
4758224 Siposs Jul 1988 A
4770413 Green Sep 1988 A
4792097 Kremer, Jr. et al. Dec 1988 A
4796614 Nowacki et al. Jan 1989 A
4809692 Nowacki et al. Mar 1989 A
4832015 Nowacki et al. May 1989 A
4834083 Byram et al. May 1989 A
4846168 Abiko et al. Jul 1989 A
4852561 Sperry Aug 1989 A
4907583 Wetterlin et al. Mar 1990 A
4911157 Miller Mar 1990 A
4940051 Lankinen Jul 1990 A
4981295 Belman et al. Jan 1991 A
4984158 Hillsman Jan 1991 A
5012803 Foley et al. May 1991 A
5012804 Foley et al. May 1991 A
5020527 Dessertine Jun 1991 A
5020530 Miller Jun 1991 A
5033463 Cocozza Jul 1991 A
5040527 Larson et al. Aug 1991 A
5042467 Foley Aug 1991 A
5048729 Pritchard Sep 1991 A
5054477 Terada et al. Oct 1991 A
5054478 Grychowski et al. Oct 1991 A
5078131 Foley Jan 1992 A
5086765 Levine Feb 1992 A
5109840 Daleiden May 1992 A
5165392 Small, Jr. Nov 1992 A
5167506 Kilis et al. Dec 1992 A
5170782 Kocinski Dec 1992 A
5178138 Walstrom et al. Jan 1993 A
5193529 Labaere Mar 1993 A
5241954 Glenn Sep 1993 A
5250287 Cocozza Oct 1993 A
5277175 Riggs et al. Jan 1994 A
5280784 Kohler Jan 1994 A
5297543 Larson et al. Mar 1994 A
5299565 Brown Apr 1994 A
5301662 Bagwell et al. Apr 1994 A
5301663 Small, Jr. Apr 1994 A
5309900 Knoch et al. May 1994 A
5312046 Knoch et al. May 1994 A
5318015 Mansson et al. Jun 1994 A
5349947 Newhouse et al. Sep 1994 A
5357951 Ratner Oct 1994 A
5363842 Mishelevich et al. Nov 1994 A
D355029 Kinneir et al. Jan 1995 S
5385140 Smith Jan 1995 A
5392648 Robertson Feb 1995 A
5398714 Price Mar 1995 A
5427089 Kraemer Jun 1995 A
5456249 Kirk Oct 1995 A
5458136 Jaser et al. Oct 1995 A
5461695 Knoch Oct 1995 A
5477849 Fry Dec 1995 A
5479920 Piper et al. Jan 1996 A
5487378 Robertson et al. Jan 1996 A
5497765 Praud et al. Mar 1996 A
5497872 Pennino Mar 1996 A
5501214 Sabo Mar 1996 A
5505192 Samiotes et al. Apr 1996 A
5505193 Ballini et al. Apr 1996 A
5505194 Adjei et al. Apr 1996 A
5511538 Haber et al. Apr 1996 A
5511539 Lien Apr 1996 A
5515842 Ramseyer et al. May 1996 A
5518179 Humberstone et al. May 1996 A
5520166 Ritson et al. May 1996 A
5533497 Ryder Jul 1996 A
5533501 Denyer Jul 1996 A
5544647 Jewett et al. Aug 1996 A
5549102 Lintl et al. Aug 1996 A
5562093 Gerson Oct 1996 A
5570682 Johnson Nov 1996 A
5575282 Knoch et al. Nov 1996 A
5584285 Salter et al. Dec 1996 A
5596982 Blaha-Schnabel Jan 1997 A
5598839 Niles et al. Feb 1997 A
5613489 Miller et al. Mar 1997 A
5617844 King Apr 1997 A
5622162 Johansson et al. Apr 1997 A
5629032 Pennino May 1997 A
5630409 Bono et al. May 1997 A
5645049 Foley et al. Jul 1997 A
5647345 Saul Jul 1997 A
5657853 Pennino Aug 1997 A
5657926 Toda Aug 1997 A
5658221 Hougen Aug 1997 A
5676130 Gupte et al. Oct 1997 A
5687912 Denyer Nov 1997 A
5701886 Ryatt Dec 1997 A
5724959 McAughey et al. Mar 1998 A
5724962 Vidgren et al. Mar 1998 A
5738087 King Apr 1998 A
5740966 Blaha-Schnabel Apr 1998 A
5752505 Ohki et al. May 1998 A
5755221 Bisgaard May 1998 A
5765553 Richards et al. Jun 1998 A
5775320 Patton et al. Jul 1998 A
5792057 Rubsamen et al. Aug 1998 A
5803078 Brauner Sep 1998 A
5816240 Komesaroff Oct 1998 A
5823179 Grychowski et al. Oct 1998 A
5840279 Narodylo et al. Nov 1998 A
5848588 Foley et al. Dec 1998 A
5855202 Andrade Jan 1999 A
5875774 Clementi et al. Mar 1999 A
5881718 Mortenson et al. Mar 1999 A
5889832 Bonnamour et al. Mar 1999 A
5890998 Hougen Apr 1999 A
5896857 Hely et al. Apr 1999 A
5925831 Storsved Jul 1999 A
5957389 Wunderlich et al. Sep 1999 A
6000394 Blaha-Schnabel et al. Dec 1999 A
6026807 Puderbaugh et al. Feb 2000 A
6026808 Armer et al. Feb 2000 A
6026809 Abrams et al. Feb 2000 A
6039042 Sladek Mar 2000 A
6044841 Verdun et al. Apr 2000 A
6044859 Davis Apr 2000 A
6085741 Becker Jul 2000 A
6089105 Ricciardelli Jul 2000 A
6102036 Slutsky et al. Aug 2000 A
6106479 Wunderlich et al. Aug 2000 A
6116233 Denyer et al. Sep 2000 A
6123075 Kirk Sep 2000 A
6129080 Pitcher et al. Oct 2000 A
6131568 Denyer et al. Oct 2000 A
6138673 Shepherd Oct 2000 A
6176237 Wunderlich et al. Jan 2001 B1
6179164 Fuchs Jan 2001 B1
6223745 Hammarlund et al. May 2001 B1
6228346 Zhang et al. May 2001 B1
6237589 Denyer et al. May 2001 B1
6240917 Andrade Jun 2001 B1
6257231 Shick et al. Jul 2001 B1
6293279 Schmidt et al. Sep 2001 B1
6345617 Engelbreth et al. Feb 2002 B1
6367471 Genosar et al. Apr 2002 B1
6412481 Bienvenu et al. Jul 2002 B1
6435176 Berg et al. Aug 2002 B1
6435177 Schmidt et al. Aug 2002 B1
6450163 Blacker et al. Sep 2002 B1
6464388 Ligouzat Oct 2002 B2
6481438 Gallem et al. Nov 2002 B1
6513519 Gallem Feb 2003 B2
6513727 Jaser et al. Feb 2003 B1
6514177 Brugger et al. Feb 2003 B1
6543448 Smith et al. Apr 2003 B1
6557549 Schmidt et al. May 2003 B2
6584971 Denyer et al. Jul 2003 B1
6595203 Bird Jul 2003 B1
6606990 Stapleton et al. Aug 2003 B2
6606992 Schuler et al. Aug 2003 B1
6612303 Grychowski et al. Sep 2003 B1
6644304 Grychowski et al. Nov 2003 B2
D483860 Knoch Dec 2003 S
6679251 Gallem et al. Jan 2004 B1
6679252 Sladek Jan 2004 B2
6732944 Litherland et al. May 2004 B2
6748945 Grychowski et al. Jun 2004 B2
6752145 Bonney et al. Jun 2004 B1
6848443 Schmidt et al. Feb 2005 B2
6929003 Blacker et al. Aug 2005 B2
6962151 Knoch et al. Nov 2005 B1
6978941 Litherland et al. Dec 2005 B2
6983747 Gallem et al. Jan 2006 B2
6994083 Foley et al. Feb 2006 B2
7013896 Schmidt Mar 2006 B2
7051731 Rogerson May 2006 B1
7059320 Feiner et al. Jun 2006 B2
7077126 Kummer et al. Jul 2006 B2
7080643 Grychowski et al. Jul 2006 B2
7104463 Litherland et al. Sep 2006 B2
7131440 Sonntag Nov 2006 B2
7261102 Barney et al. Aug 2007 B2
7360537 Snyder et al. Apr 2008 B2
7559322 Foley et al. Jul 2009 B2
7562656 Gallem et al. Jul 2009 B2
8074641 Gallem et al. Dec 2011 B2
20010013341 Gallem Aug 2001 A1
20010032643 Hochrainer et al. Oct 2001 A1
20010054421 Jaser et al. Dec 2001 A1
20020005196 Brugger Jan 2002 A1
20020020762 Selzer et al. Feb 2002 A1
20020056448 Stapleton et al. May 2002 A1
20020157663 Blacker et al. Oct 2002 A1
20030005929 Grychowski et al. Jan 2003 A1
20030015193 Grychowski et al. Jan 2003 A1
20030037785 Sonntag Feb 2003 A1
20030037788 Gallem et al. Feb 2003 A1
20030089368 Zhao May 2003 A1
20030136499 Boiteau Jul 2003 A1
20030205226 Gallem et al. Nov 2003 A1
20030226562 Schmidt et al. Dec 2003 A1
20040031485 Rustad et al. Feb 2004 A1
20040060556 Halamish Apr 2004 A1
20040089295 Gallem et al. May 2004 A1
20040094148 Lulla et al. May 2004 A1
20040173209 Grychowski et al. Sep 2004 A1
20040231665 Lieberman et al. Nov 2004 A1
20040250816 Kummer et al. Dec 2004 A1
20050039741 Gallem et al. Feb 2005 A1
20050056274 Kunschir Mar 2005 A1
20050183718 Wuttke et al. Aug 2005 A1
20050205085 Blacker et al. Sep 2005 A1
20050224076 Pfichner et al. Oct 2005 A1
20050244339 Jauernig et al. Nov 2005 A1
20060011196 Gallem et al. Jan 2006 A2
20060048772 Borgschulte Mar 2006 A1
20060054166 Knoch et al. Mar 2006 A1
20060057073 Lintz et al. Mar 2006 A1
20060065267 Tran et al. Mar 2006 A1
20060102172 Feiner et al. May 2006 A1
20060102178 Feiner et al. May 2006 A1
20060157052 Foley et al. Jul 2006 A1
20060162723 Selzer et al. Jul 2006 A1
20060207591 Gallem et al. Sep 2006 A1
20060213503 Borgschulte et al. Sep 2006 A1
20060254578 Boehm et al. Nov 2006 A1
20060254579 Grychowski et al. Nov 2006 A1
20060289002 Hetzer et al. Dec 2006 A1
20070023036 Grychowski et al. Feb 2007 A1
Foreign Referenced Citations (51)
Number Date Country
2064860 Mar 1991 CA
2124519 Nov 1994 CA
199 02 847 May 2000 DE
0 009 667 Apr 1980 EP
0 015 247 Sep 1980 EP
0 134 847 Mar 1985 EP
0 289 563 Nov 1988 EP
0 347 779 Dec 1989 EP
0 372 148 Jun 1990 EP
0 414 536 Feb 1991 EP
0 475 257 Mar 1992 EP
0 514 085 Nov 1992 EP
0 548 152 Jun 1993 EP
0 587 380 Mar 1994 EP
0 641 570 Mar 1995 EP
0 678 306 Oct 1995 EP
0 820 780 Jan 1998 EP
0 855 224 Jul 1998 EP
0 938 906 Sep 1999 EP
0 938 908 Sep 1999 EP
1 358 901 Dec 2003 EP
1.070.292 Jul 1954 FR
497530 Apr 1938 GB
675524 Oct 1949 GB
975754 Nov 1964 GB
1017032 Jan 1966 GB
2 000 555 Jan 1979 GB
1598081 Sep 1981 GB
2253200 Feb 1991 GB
2 299 512 Oct 1996 GB
55-40595 Mar 1980 JP
WO 9100117 Jan 1991 WO
WO 9220391 Nov 1992 WO
WO 9311817 Jun 1993 WO
WO 9520414 Aug 1995 WO
WO 9632149 Oct 1996 WO
WO 9701365 Jan 1997 WO
9819727 May 1998 WO
WO 9826827 Jun 1998 WO
WO 9826828 Jun 1998 WO
WO 9841265 Sep 1998 WO
WO 9916490 Apr 1999 WO
WO 9940959 Aug 1999 WO
WO 0027455 May 2000 WO
WO 0059565 Oct 2000 WO
WO 0176671 Oct 2001 WO
0204056 Jan 2002 WO
0205630 Jan 2002 WO
WO 03053500 Jul 2003 WO
03097142 Nov 2003 WO
WO 2010054083 May 2010 WO
Non-Patent Literature Citations (41)
Entry
Bisgaard, et al., “A non-electrostatic spacer for aerosol delivery”, Archives of Diseases in Childhood, 1995; 73:p. 226-230.
Bisgaard, “Automatic Actuation of a Dry Powder Inhaler into a Nonelectrostatic Space”, AM J Respir Crit Care Med 1998; vol. 157 pp. 518-521.
“AARC Clinical Practice Guideline: Use of Positive Airway Pressure Adjuncts to Bronchial Hygiene Therapy.” Respiratory Care. vol. 38, No. 5. May 1993. pp. 516-520.
Christensen et al. “Treatment of Bronchial Asthma with Terbutaline Inhaled by Conespacer Combined with Positive Expiratory Pressure Mask.” Chest 100. vol. 2. Aug. 1991. pp. 317-321.
Hickey et al. “Inhalation Aerosols: Physical and Biological Basis for Therapy.” Marcel Dekker, Inc. pp. 418-435.
Anderson et al. “A new Mode of Administration Nebulized Bronchodilator in Severe Bronchospasm.” Eur. J. Respir. Dis. Suppl. 119. vol. 63. 1982. pp. 97-100.
Rau et al. “Combining a Positive Expiratory Pressure Device with a Metered-Dose Inhaler Reservoir System Using Chlorofluorocarbon Albuterol and Hydrofluoroalkane Albuterol: Effect on Does and Particle Size Distributions.” Respiratory Care. vol. 45. No. 3. 2000. pp. 320-326.
Rau. Respiratory Care Pharmacology 4th Edition. 1994. Mosby. pp. 256.261.
Meeran et al. “Oral and Inhaled Corticosteroids Reduce Bone Formation as Shown by Plasma Osteocalcin Levels.” Am. J. Respir. Crit. Care. Med. vol. 751. 1995. pp. 333-336.
Merriam-Webster's Collegiate Dictionary, Tenth Ed. ISBN 0-87779-707-2. 1993. pp. 86.
Mahlmeister et al. “Positive-Expiratory-Pressure Mask Therapy: Theoretical and Practical Considerations and a Review of the Literature.” Respiratory Care. vol. 36. No. 11. 1991. pp. 1218-1229.
Newman. “Aerosol Deposition Considerations in Inhalation Therapy.” Chest. vol. 8. No. 2. 1985. pp. 152-160.
Contents. “Technology Showcase: Adjuncts to Bronchial Hygiene Therapy.” AARC Times. 1998. pp. 12-14.
Ventlab Corporation. “Ventlab BreatheRite.” http://www.ventlab.com/mdi.htm. 2000.
Pamphlet for “Part PEP System. Part No. 18F61.” 2001. pp. 1-4.
Pamphlet for “TheraPEP: Positive Expiratory Pressure Therapy System.” No. 20-112. 2001. pp. 1-5.
Photographs for Ventlab BreatheRite holding chamber. 3 pages.
Callahan. “K981944—BreatheRite.” Letter from Dept. of Health & Human Services with enclosures. 1998. pp. 1-3.
AeroChamber product, allegedly by Trudell Medical International, dates unknown. (unavailable).
AeroChamber Plus, allegedly by Trudell Medical International, dates unknown. (unavailable).
AeroPEP Plus, allegedly by Trudell Medical International, dates unknown. (unavailable).
AeroTrach, allegedly by Trudell Medical International, dates unknown. (unavailable).
BreatheRite, allegedly by Ventlab Corporation, dates unknown. (unavailable).
Nebuhaler, allegedly by Astra Pharmaceuticals, Ltd., dates unknown. (unavailable).
BagEasy Disposable Resuscitator, allegedly by Respironics Inc., dates unknown. (unavailable).
Optichamber, allegedly by Respironics Inc., dates unknown. (unavailable).
ProChamber, allegedly by Respironics Inc., dates unknown. (unavailable).
MicroHaler, allegedly by Pfeiffer, dates unknown. (unavailable).
Duckbill valves, allegedly by Vernay Labs. Inc., dates unknown.
Defendant's Preliminary Invalidity Contentions and Claim Charts, filed Dec. 2, 2009 in PRE Holding, Inc. v. Monaghan Medical Corp., U.S. District Court for Eastern District of Virginia, Civil No. 3:09-cv-458.
Pamphlet for “AeroKat: Feling Aerosol Chamber” 2 pages; www.aerokat.com; allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroChamber Max . . . Breath Easier Anti-Static Valved Holding Chamber” 2 pages; www.trudellmed.com; allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroChamber Plus with Flow-Vu Valved Holding Chamber” 2 pages; allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroChamber VHC just for you” 2 pages; www.trudellmed.com; allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroChamber® Brand helps deliver medication where it is needed—deep in the lungs” 2 pages; allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroChamber Plus Valved Holding Chamber” 2 pages; www.trudellmed.com; allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroPEP Plus Valved Holding Chamber” 2 pages allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroTrach Plus Anti-Static Valved Holding Chamber” 1 page allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroHippus Equine Aerosol Chamber” 2 pages, www.aerohippus.com allegedly by Trudell Medical International (date unknown).
Pamphlet for “AeroDawg Canine Aerosol Chamber” 2 pages www.aerodawg.com allegedly by Trudell Medical International (date unknown).
Peter W. Barry et al., “The output of budesonide from spacer devices assessed under simulated breathing conditions”, J. Allergy Clin Immunol, Dec. 1999, p. 1205-1210, vol. 104 No. 6.
Continuations (4)
Number Date Country
Parent 13288479 Nov 2011 US
Child 13901143 US
Parent 12332976 Dec 2008 US
Child 13288479 US
Parent 10943542 Sep 2004 US
Child 12332976 US
Parent 10137007 May 2002 US
Child 10943542 US